GC101 TIL

GC101 TIL (GC101) is a tumour-infiltrating lymphocyte therapy developed by Shanghai Juncell Therapeutics. Its targets are PD-1, BRAF and MEK1/2 (the sponsor names melanoma and non-small cell lung cancer (solid tumours)). The sponsor states: An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration. ClinicalTrials.gov describes the intervention as: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for r. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma. The largest, NCT06703398, plans to enrol 98 participants with primary completion expected 2026-05-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.